Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Atossa Genetics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Atossa Genetics, Inc. (“Atossa” or the “Company”) (NASDAQ: ATOS) of the December 9, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Atossa and certain executives.
A complaint has been filed on behalf of all persons who purchased or otherwise acquired Atossa shares between November 8, 2012 and October 4, 2013 (the “Class Period”) in the Western District of Washington.
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that throughout the Class Period Atossa issued false and/or misleading statements regarding the Company’s improperly marketing of its devices utilizing certain promotional claims concerning the ForeCYTE Breast Health Test and the MASCT device.
On October 4, 2013, Atossa announced that it was initiating a recall to remove the ForeCYTE Breast Health Test and the MASCT device from the market due to concerns of the FDA communicated in a warning letter.
Following this news, the Company’s stock declined $2.47 per share, or over 46%, to close at $2.85 per share on October 7, 2013.
If you invested in Atossa stock or options between November 8, 2012 and October 4, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Atossa’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.